SCOPUS 정보 검색 플랫폼

BMC Research Notes

Volumn 3, Issue , 2010, Pages

Advanced non-small cell lung cancer: on relapse rechallenge the tumor, not the patient

(2) Froudarakis, Marios E a Briasoulis, Evangelos b

a DEMOCRITUS UNIVERSITY OF THRACE (Greece)

b UNIVERSITY OF IOANNINA (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955395416 PISSN: None EISSN: 17560500 Source Type: Journal
DOI: 10.1186/1756-0500-3-195 Document Type: Note

Times cited : (9)

References (24)

1
- 52649131951
- Lung cancer
- 10.1056/NEJMra0802714. 18815398
- Lung cancer. RS Herbst JV Heymach SM Lippman, N Engl J Med 2008 359 13 1367 1380 10.1056/NEJMra0802714 18815398
- (2008) N Engl J Med , vol.359 , Issue.13 , pp. 1367-1380
- Herbst, R.S.¹ Heymach, J.V.² Lippman, S.M.³

2
- 65349124698
- Current treatments for advanced stage non-small cell lung cancer
- 10.1513/pats.200809-110LC. 19349493
- Current treatments for advanced stage non-small cell lung cancer. TE Stinchcombe MA Socinski, Proc Am Thorac Soc 2009 6 2 233 241 10.1513/pats.200809-110LC 19349493
- (2009) Proc Am Thorac Soc , vol.6 , Issue.2 , pp. 233-241
- Stinchcombe, T.E.¹ Socinski, M.A.²

3
- 74949133978
- American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer
- 10.1200/JCO.2009.23.5622. 19917871
- American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. CG Azzoli S Baker Jr S Temin W Pao T Aliff J Brahmer DH Johnson JL Laskin G Masters D Milton, et al. J Clin Oncol 2009 27 36 6251 6266 10.1200/JCO.2009.23.5622 19917871
- (2009) J Clin Oncol , vol.27 , Issue.36 , pp. 6251-6266
- Azzoli, C.G.¹ Baker Jr., S.² Temin, S.³ Pao, W.⁴ Aliff, T.⁵ Brahmer, J.⁶ Johnson, D.H.⁷ Laskin, J.L.⁸ Masters, G.⁹ Milton, D.¹⁰

4
- 41749112477
- Second-line treatment of advanced non-small cell lung cancer
- DOI 10.1097/JTO.0b013e318168c815, PII 0124389420080400000020
- Second-line treatment of advanced non-small cell lung cancer. C Gridelli A Ardizzoni F Ciardiello N Hanna JV Heymach F Perrone R Rosell FA Shepherd N Thatcher J Vansteenkiste, et al. J Thorac Oncol 2008 3 4 430 440 10.1097/JTO.0b013e318168c815 18379366 (Pubitemid 351489488)
- (2008) Journal of Thoracic Oncology , vol.3 , Issue.4 , pp. 430-440
- Gridelli, C.¹ Ardizzoni, A.² Ciardiello, F.³ Hanna, N.⁴ Heymach, J.V.⁵ Perrone, F.⁶ Rosell, R.⁷ Shepherd, F.A.⁸ Thatcher, N.⁹ Vansteenkiste, J.¹⁰ De Petris, L.¹¹ Di Maio, M.¹² De Marinis, F.¹³

5
- 46849093651
- Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy
- 10.2214/AJR.07.2848. 18562736
- Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. A Sabir R Schor-Bardach CJ Wilcox S Rahmanuddin MB Atkins JB Kruskal S Signoretti VD Raptopoulos SN Goldberg, AJR Am J Roentgenol 2008 191 1 133 139 10.2214/AJR.07.2848 18562736
- (2008) AJR Am J Roentgenol , vol.191 , Issue.1 , pp. 133-139
- Sabir, A.¹ Schor-Bardach, R.² Wilcox, C.J.³ Rahmanuddin, S.⁴ Atkins, M.B.⁵ Kruskal, J.B.⁶ Signoretti, S.⁷ Raptopoulos, V.D.⁸ Goldberg, S.N.⁹

6
- 33749629381
- Non-small cell lung cancer: second-line and beyond
- 10.1093/annonc/mdl245. 17018760
- Non-small cell lung cancer: second-line and beyond. RA Stahel, Ann Oncol 2006 17 Suppl 10 97 100 10.1093/annonc/mdl245 17018760
- (2006) Ann Oncol , vol.17 , Issue.SUPPL. 10 , pp. 2497-100
- Stahel, R.A.¹

7
- 34247871456
- Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: A systematic review and practice guideline
- 10.1097/01243894-200611000-00021. 17409993
- Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Noble PM Ellis JA Mackay WK Evans, J Thorac Oncol 2006 1 9 1042 1058 10.1097/01243894-200611000-00021 17409993
- (2006) J Thorac Oncol , vol.1 , Issue.9 , pp. 1042-1058
- Noble, J.¹ Ellis, P.M.² Mackay, J.A.³ Evans, W.K.⁴

8
- 77449098773
- Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426
- 10.1200/JCO.2009.23.6406. 19841321
- Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. AA Adjei SJ Mandrekar GK Dy JR Molina DR Gandara KL Ziegler PJ Stella KM Rowland Jr SE Schild RG Zinner, J Clin Oncol 2010 28 4 614 619 10.1200/JCO.2009.23.6406 19841321
- (2010) J Clin Oncol , vol.28 , Issue.4 , pp. 614-619
- Adjei, A.A.¹ Mandrekar, S.J.² Dy, G.K.³ Molina, J.R.⁴ Gandara, D.R.⁵ Ziegler, K.L.⁶ Stella, P.J.⁷ Rowland Jr., K.M.⁸ Schild, S.E.⁹ Zinner, R.G.¹⁰

9
- 42049107120
- Considerations for second-line therapy of non-small cell lung cancer
- 10.1634/theoncologist.13-S1-28. 18263772
- Considerations for second-line therapy of non-small cell lung cancer. TE Stinchcombe MA Socinski, Oncologist 2008 13 Suppl 1 28 36 10.1634/theoncologist. 13-S1-28 18263772
- (2008) Oncologist , vol.13 , Issue.SUPPL. 1 , pp. 28-36
- Stinchcombe, T.E.¹ Socinski, M.A.²

10
- 11444253115
- Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer
- 10.1016/j.lungcan.2004.07.040. 15639724
- Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. TA Hensing MJ Schell JH Lee MA Socinski, Lung Cancer 2005 47 2 253 259 10.1016/j.lungcan.2004.07.040 15639724
- (2005) Lung Cancer , vol.47 , Issue.2 , pp. 253-259
- Hensing, T.A.¹ Schell, M.J.² Lee, J.H.³ Socinski, M.A.⁴

11
- 76249105307
- Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trials
- 10.1016/j.ejca.2009.12.013. 20045311
- Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. M Di Maio N Lama A Morabito EF Smit V Georgoulias K Takeda E Quoix D Hatzidaki FM Wachters V Gebbia, et al. Eur J Cancer 46 4 735 743 10.1016/j.ejca.2009.12.013 20045311
- Eur J Cancer , vol.46 , Issue.4 , pp. 735-743
- Di Maio, M.¹ Lama, N.² Morabito, A.³ Smit, E.F.⁴ Georgoulias, V.⁵ Takeda, K.⁶ Quoix, E.⁷ Hatzidaki, D.⁸ Wachters, F.M.⁹ Gebbia, V.¹⁰

12
- 0037050352
- Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
- DOI 10.1056/NEJMoa011954
- Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. JH Schiller D Harrington CP Belani C Langer A Sandler J Krook J Zhu DH Johnson, N Engl J Med 2002 346 2 92 98 10.1056/NEJMoa011954 11784875 (Pubitemid 34438899)
- (2002) New England Journal of Medicine , vol.346 , Issue.2 , pp. 92-98
- Schiller, J.H.¹ Harrington, D.² Belani, C.P.³ Langer, C.⁴ Sandler, A.⁵ Krook, J.⁶ Zhu, J.⁷ Johnson, D.H.⁸

13
- 55849124736
- Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma
- 10.1002/cncr.23921. 18823054
- Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma. ME Froudarakis A Pataka P Pappas S Anevlavis E Argiana M Nikolaidou G Kouliatis S Pozova M Marselos D Bouros, Cancer 2008 113 10 2752 2760 10.1002/cncr.23921 18823054
- (2008) Cancer , vol.113 , Issue.10 , pp. 2752-2760
- Froudarakis, M.E.¹ Pataka, A.² Pappas, P.³ Anevlavis, S.⁴ Argiana, E.⁵ Nikolaidou, M.⁶ Kouliatis, G.⁷ Pozova, S.⁸ Marselos, M.⁹ Bouros, D.¹⁰

14
- 0036042916
- Second-line chemotherapy for non-small cell lung cancer
- Second-line chemotherapy for non-small cell lung cancer. X Bonfill C Serra M Sacristan M Nogue F Losa J Montesinos, Cochrane Database Syst Rev 2002 2 D002804
- Cochrane Database Syst Rev , vol.2002 , Issue.2
- Bonfill, X.¹ Serra, C.² Sacristan, M.³ Nogue, M.⁴ Losa, F.⁵ Montesinos, J.⁶

15
- 77954753209
- Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer
- 10.1186/1756-0500-3-164. 20537187
- Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer. R Belbaraka O Trédan I Ray-Coquard G Chvetzoff A Bajard D Pérol N Ismaili M Ismaili H Errihani T Bachelot, et al. BMC Res Notes 2010 3 164 10.1186/1756-0500-3-164 20537187
- (2010) BMC Res Notes , vol.3 , pp. 164
- Belbaraka, R.¹ Trédan, O.² Ray-Coquard, I.³ Chvetzoff, G.⁴ Bajard, A.⁵ Pérol, D.⁶ Ismaili, N.⁷ Ismaili, M.⁸ Errihani, H.⁹ Bachelot, T.¹⁰

16
- 69949162760
- Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
- 10.1056/NEJMoa0810699. 19692680
- Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. TS Mok YL Wu S Thongprasert CH Yang DT Chu N Saijo P Sunpaweravong B Han B Margono Y Ichinose, et al. N Engl J Med 2009 361 10 947 957 10.1056/NEJMoa0810699 19692680
- (2009) N Engl J Med , vol.361 , Issue.10 , pp. 947-957
- Mok, T.S.¹ Wu, Y.L.² Thongprasert, S.³ Yang, C.H.⁴ Chu, D.T.⁵ Saijo, N.⁶ Sunpaweravong, P.⁷ Han, B.⁸ Margono, B.⁹ Ichinose, Y.¹⁰

17
- 34548275962
- Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer
- 10.4161/cbt.6.3.3994. 17387266
- Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. DH Roukos S Murray E Briasoulis, Cancer Biol Ther 2007 6 3 308 312 10.4161/cbt.6.3.3994 17387266
- (2007) Cancer Biol Ther , vol.6 , Issue.3 , pp. 308-312
- Roukos, D.H.¹ Murray, S.² Briasoulis, E.³

18
- 68549140332
- Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
- 10.1038/nrclinonc.2009.62. 19483740
- Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. H Linardou IJ Dahabreh D Bafaloukos P Kosmidis S Murray, Nat Rev Clin Oncol 2009 6 6 352 366 10.1038/nrclinonc.2009.62 19483740
- (2009) Nat Rev Clin Oncol , vol.6 , Issue.6 , pp. 352-366
- Linardou, H.¹ Dahabreh, I.J.² Bafaloukos, D.³ Kosmidis, P.⁴ Murray, S.⁵

19
- 54049153188
- First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer
- 10.1164/rccm.200803-389OC. 18583573
- First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer. JY Wu CJ Yu CH Yang SG Wu YH Chiu CH Gow YC Chang YC Hsu PF Wei JY Shih, et al. Am J Respir Crit Care Med 2008 178 8 847 853 10.1164/rccm.200803-389OC 18583573
- (2008) Am J Respir Crit Care Med , vol.178 , Issue.8 , pp. 847-853
- Wu, J.Y.¹ Yu, C.J.² Yang, C.H.³ Wu, S.G.⁴ Chiu, Y.H.⁵ Gow, C.H.⁶ Chang, Y.C.⁷ Hsu, Y.C.⁸ Wei, P.F.⁹ Shih, J.Y.¹⁰

20
- 74949117339
- Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer
- 10.1158/1078-0432.CCR-09-1660. 20028749
- Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. IJ Dahabreh H Linardou F Siannis P Kosmidis D Bafaloukos S Murray, Clin Cancer Res 2010 16 1 291 303 10.1158/1078-0432.CCR-09-1660 20028749
- (2010) Clin Cancer Res , vol.16 , Issue.1 , pp. 291-303
- Dahabreh, I.J.¹ Linardou, H.² Siannis, F.³ Kosmidis, P.⁴ Bafaloukos, D.⁵ Murray, S.⁶

21
- 17244366780
- Third-line chemotherapy for advanced non-small-cell lung cancer - Is there enough evidence to support its use?
- 10.1016/S1726-4901(09)70240-0. 15850063
- Third-line chemotherapy for advanced non-small-cell lung cancer - is there enough evidence to support its use? CH Yang, J Chin Med Assoc 2005 68 4 160 161 10.1016/S1726-4901(09)70240-0 15850063
- (2005) J Chin Med Assoc , vol.68 , Issue.4 , pp. 160-161
- Yang, C.H.¹

22
- 0037214171
- A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer
- 10.1016/S0169-5002(02)00308-2. 12499095
- A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. E Massarelli F Andre DD Liu JJ Lee M Wolf A Fandi J Ochs T Le Chevalier F Fossella RS Herbst, Lung Cancer 2003 39 1 55 61 10.1016/S0169-5002(02)00308-2 12499095
- (2003) Lung Cancer , vol.39 , Issue.1 , pp. 55-61
- Massarelli, E.¹ Andre, F.² Liu, D.D.³ Lee, J.J.⁴ Wolf, M.⁵ Fandi, A.⁶ Ochs, J.⁷ Le Chevalier, T.⁸ Fossella, F.⁹ Herbst, R.S.¹⁰

23
- 19944429409
- Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)
- 10.1093/annonc/mdi018. 15598944
- Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). R Gervais A Ducolone JL Breton D Braun B Lebeau F Vaylet D Debieuvre JL Pujol J Tredaniel P Clouet, et al. Ann Oncol 2005 16 1 90 96 10.1093/annonc/mdi018 15598944
- (2005) Ann Oncol , vol.16 , Issue.1 , pp. 90-96
- Gervais, R.¹ Ducolone, A.² Breton, J.L.³ Braun, D.⁴ Lebeau, B.⁵ Vaylet, F.⁶ Debieuvre, D.⁷ Pujol, J.L.⁸ Tredaniel, J.⁹ Clouet, P.¹⁰

24
- 70350212970
- Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer
- 10.1158/1078-0432.CCR-09-0970. 19808873
- Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. E Briasoulis P Pappas C Puozzo C Tolis G Fountzilas U Dafni M Marselos N Pavlidis, Clin Cancer Res 2009 15 20 6454 6461 10.1158/1078-0432.CCR-09-0970 19808873
- (2009) Clin Cancer Res , vol.15 , Issue.20 , pp. 6454-6461
- Briasoulis, E.¹ Pappas, P.² Puozzo, C.³ Tolis, C.⁴ Fountzilas, G.⁵ Dafni, U.⁶ Marselos, M.⁷ Pavlidis, N.⁸

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.